Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva

被引:9
作者
Yamamoto, Hirofumi [1 ]
Sakai, Naoki [2 ]
Ohte, Satoshi [3 ]
Sato, Tomohiro [4 ]
Sekimata, Katsuhiko [1 ]
Matsumoto, Takehisa [2 ]
Nakamura, Kana [2 ]
Watanabe, Hisami [2 ]
Mishima-Tsumagari, Chiemi [2 ]
Tanaka, Akiko [2 ]
Hashizume, Yoshinobu [5 ]
Honma, Teruki [4 ]
Katagiri, Takenobu [6 ]
Miyazono, Kohei [7 ]
Tomoda, Hiroshi [3 ]
Shirouzu, Mikako [2 ]
Koyama, Hiroo [1 ]
机构
[1] RIKEN Ctr Sustainable Resource Sci, Drug Discovery Chem Platform Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan
[2] RIKEN Ctr Biosystems Dynam Res, Drug Discovery Struct Biol Platform Unit, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan
[3] Kitasato Univ, Grad Sch Pharmaceut Sci, Dept Microbial Chem, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan
[4] RIKEN Ctr Biosyst Dynam Res, Drug Discovery Computat Chem Platform Unit, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan
[5] RIKEN Program Drug Discovery & Med Technol Platfo, 2-1 Hirosawa, Wako, Saitama 3510198, Japan
[6] Saitama Med Univ, Res Ctr Genom Med, Div Biomed Sci, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan
[7] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan
关键词
Fibrodysplasia ossificans progressiva (FOP); Activin receptor-like kinase-2 (ALK2); Bicyclic pyrazole derivatives;
D O I
10.1016/j.bmcl.2021.127858
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Mutant activin receptor-like kinase-2 (ALK2) is associated with the pathogenesis of fibrodysplasia ossificans progressiva, making it an attractive target for therapeutic intervention. We synthesized a new series of bicyclic pyrazoles and evaluated their mutant ALK2 enzyme inhibitory activities, leading to the identification of 8 as the most potent inhibitor. This compound showed moderate microsomal metabolic stability and human ether-a-gogo related gene (hERG) safety. In C2C12 cells carrying mutant ALK2 (R206H), 8 efficiently inhibited the bone morphogenetic protein (BMP)-induced alkaline phosphatase activity.
引用
收藏
页数:5
相关论文
共 15 条
[1]   ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma [J].
Carvalho, Diana ;
Taylor, Kathryn R. ;
Olaciregui, Nagore Gene ;
Molinari, Valeria ;
Clarke, Matthew ;
Mackay, Alan ;
Ruddle, Ruth ;
Henley, Alan ;
Valenti, Melanie ;
Hayes, Angela ;
Brandon, Alexis De Haven ;
Eccles, Suzanne A. ;
Raynaud, Florence ;
Boudhar, Aicha ;
Monje, Michelle ;
Popov, Sergey ;
Moore, Andrew S. ;
Mora, Jaume ;
Cruz, Ofelia ;
Vinci, Mara ;
Brennan, Paul E. ;
Bullock, Alex N. ;
Carcaboso, Angel Montero ;
Jones, Chris .
COMMUNICATIONS BIOLOGY, 2019, 2 (1)
[2]  
Eickmeier C, 2006, [No title captured], Patent No. [WO 2006/103038, 2006103038]
[3]   Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva [J].
Fukuda, Toru ;
Kohda, Masakazu ;
Kanomata, Kazuhiro ;
Nojima, Junya ;
Nakamura, Atsushi ;
Kamizono, Jyunji ;
Noguchi, Yasuo ;
Iwakiri, Kiyofumi ;
Kondo, Takeo ;
Kurose, Junichi ;
Endo, Ken-ichi ;
Awakura, Takeshi ;
Fukushi, Junichi ;
Nakashima, Yasuharu ;
Chiyonobu, Tomohiro ;
Kawara, Akira ;
Nishida, Yoshihiro ;
Wada, Ikuo ;
Akita, Masumi ;
Komori, Tetsuo ;
Nakayama, Konosuke ;
Nanba, Akira ;
Maruki, Yuichi ;
Yoda, Tetsuya ;
Tomoda, Hiroshi ;
Yu, Paul B. ;
Shore, Eileen M. ;
Kaplan, Frederick S. ;
Miyazono, Kohei ;
Matsuoka, Masaru ;
Ikebuchi, Kenji ;
Ohtake, Akira ;
Oda, Hiromi ;
Jimi, Eijiro ;
Owan, Ichiro ;
Okazaki, Yasushi ;
Katagiri, Takenobu .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (11) :7149-7156
[4]   ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis [J].
Hoeman, Christine M. ;
Cordero, Francisco J. ;
Hu, Guo ;
Misuraca, Katie ;
Romero, Megan M. ;
Cardona, Herminio J. ;
Nazarian, Javad ;
Hashizume, Rintaro ;
McLendon, Roger ;
Yu, Paul ;
Procissi, Daniele ;
Gadd, Samantha ;
Becher, Oren J. .
NATURE COMMUNICATIONS, 2019, 10 (1)
[5]   BONE MORPHOGENETIC PROTEIN-2 CONVERTS THE DIFFERENTIATION PATHWAY OF C2C12 MYOBLASTS INTO THE OSTEOBLAST LINEAGE [J].
KATAGIRI, T ;
YAMAGUCHI, A ;
KOMAKI, M ;
ABE, E ;
TAKAHASHI, N ;
IKEDA, T ;
ROSEN, V ;
WOZNEY, JM ;
FUJISAWASEHARA, A ;
SUDA, T .
JOURNAL OF CELL BIOLOGY, 1994, 127 (06) :1755-1766
[6]   A concise synthesis of quinazolinone TGF-β RI inhibitor through one-pot three-component Suzuki-Miyaura/etherification and imidate-amide rearrangement reactions [J].
Li, Hong-yu ;
Wang, Yan ;
McMillen, William T. ;
Chatterjee, Arindam ;
Toth, John E. ;
Mundla, Sreenivasa R. ;
Voss, Matthew ;
Boyer, Robert D. ;
Sawyer, J. Scott .
TETRAHEDRON, 2007, 63 (47) :11763-11770
[7]   Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor [J].
Mohedas, Agustin H. ;
Xing, Xuechao ;
Armstrong, Kelli A. ;
Bullock, Alex N. ;
Cuny, Gregory D. ;
Yu, Paul B. .
ACS CHEMICAL BIOLOGY, 2013, 8 (06) :1291-1302
[8]   A new diketopiperazine-like inhibitor of bone morphogenetic protein-induced osteoblastic differentiation produced by marine-derived Aspergillus sp. BFM-0085 [J].
Ohte, Satoshi ;
Shiokawa, Takehiro ;
Koyama, Nobuhiro ;
Katagiri, Takenobu ;
Imada, Chiaki ;
Tomoda, Hiroshi .
JOURNAL OF ANTIBIOTICS, 2020, 73 (08) :554-558
[9]  
Pignolo RJ, 2013, PEDIATR ENDOCR REV P, V10, P437
[10]   Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches [J].
Sato, Tomohiro ;
Sekimata, Katsuhiko ;
Sakai, Naoki ;
Watanabe, Hisami ;
Mishima-Tsumagari, Chiemi ;
Taguri, Tomonori ;
Matsumoto, Takehisa ;
Fujii, Yoshifumi ;
Handa, Noriko ;
Tanaka, Akiko ;
Shirouzu, Mikako ;
Yokoyama, Shigeyuki ;
Hashizume, Yoshinobu ;
Miyazono, Kohei ;
Koyama, Hiroo ;
Honma, Teruki .
ACS OMEGA, 2020, 5 (20) :11411-11423